Financings in Brief: SurVivaLink
This article was originally published in The Gray Sheet
Executive Summary
SurVivaLink: Automated external defibrillator firm completes $11.2 mil. private placement of Series A preferred stock. Proceeds will go toward "aggressive global marketing," according to a June 17 release. Lead investors in the placement are Fidelity Ventures Limited and Fidelity Investors, L.P. Other institutional investors include CIBC Wood Gundy Ventures, The Spray Venture Fund, L.P., Wellmark, Inc., and Minnesota Management Partners I Limited. Wessels, Arnold & Henderson served as placement agent for the offering. SurVivaLink canceled plans to go public via an initial offering of 3 mil. shares last year due to poor market conditions, the firm explains ("The Gray Sheet" June 24, 1996, p. 13)...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.